FDA approves new lung cancer diagnostic tool, intraveneous opioid

Aug 10, 2020 - 03:00 PM
FDA product update

The Food and Drug Administration Friday approved the first liquid biopsy companion diagnostic that uses next-generation sequencing technology to identify patients with specific gene mutations in a deadly form of metastatic non-small cell lung cancer.

“In addition to benefitting from less invasive testing, patients are provided with a simultaneous mapping of multiple biomarkers of genomic alterations, rather than one biomarker at a time, which can translate to decreased wait times for starting treatment and provide insight into possible resistance mechanisms,” said Tim Stenzel, M.D., director of FDA’s Office of In Vitro Diagnostics and Radiological Health.

In other news, the agency Friday approved a new intraveneous opioid for managing acute pain in adults in hospital and other controlled clinical settings, such as inpatient and outpatient procedures. The drug, Olinvyk (oliceridine), has a maximum recommended daily dose limit of 27 milligrams.

Related News Articles

Headline
Blog shares insights from hospital leaders at AHA’s inaugural Rural Patient Safety Convening
Rural hospital leaders recently shared strategies and insights on improving safety culture, governance and care reliability at the AHA’s Rural Patient Safety…
Blog
AHA Patient Safety Initiative Convenes Rural Hospital Leaders to Share Trust, Resilience and Leadership Strategies
Public
Rural hospital leaders from across the country came together to share strategies and insights for improving safety culture, governance and care…
Headline
FDA sends warning letter to Philips due to quality issues 
The Food and Drug Administration sent a warning letter to Philips last month due to quality violations found at three of its medical device facilities earlier…
Blog
Smarter, Safer Hospitals: How HCA Healthcare Is Using AI to Redefine Patient Safety
Public
Cross-industry insights and new technology are helping HCA Healthcare reduce risk, improve outcomes and lead the future of high-reliability careFor Randy Fagin…
Headline
FDA vacates final rule regulating lab-developed tests as medical devices
The Food and Drug Administration released a final rule Sept. 18 that rescinds one from 2024 that applied medical device rules to laboratory-developed tests.…
Headline
AHA podcast: HCA’s AI-Driven Patient Safety Evolution, Part 1
Randy Fagin, M.D., chief quality officer at HCA Healthcare, shares insights into the organization’s bold approach to improving safety outcomes. From piloting…